| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | group | BEFREE | We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in clinical trials for other solid tumors and hematologic malignancies, alone or combined with an MEK inhibitor, PD0325901(PD). | 31272080 | 2019 | ||||
|
0.080 | AlteredExpression | group | BEFREE | Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy hematopoietic (stem) cells is urgently needed. | 29567778 | 2018 | ||||
|
0.080 | Biomarker | group | BEFREE | Treatment with BET bromodomain inhibitors is beneficial for hematologic malignancies, and they have Treg-disruptive effects in a non-small cell lung cancer (NSCLC) model. | 30087114 | 2018 | ||||
|
0.080 | Biomarker | group | BEFREE | Significant downregulation of c-Myc, a well-publicized target of BET inhibitors, was largely restricted to hematologic cancer cell lines. | 27903752 | 2017 | ||||
|
0.080 | AlteredExpression | group | BEFREE | Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1. | 28336808 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. | 24335499 | 2014 | ||||
|
0.080 | AlteredExpression | group | BEFREE | Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in part through suppression of the MYC oncogene and downstream Myc-driven pathways. | 24009722 | 2013 | ||||
|
0.080 | Biomarker | group | BEFREE | The therapeutic potential of pharmacologic inhibition of bromodomain and extraterminal (BET) proteins has recently emerged in hematological malignancies and chronic inflammation. | 23255218 | 2013 |